Outcome of Treating XXXX With @entity619 Implants.

@entity1 @entity32 @entity2194 @entity231 @entity1713 @entity1596 @entity619 @entity3225
PURPOSE: To describe the outcome in @entity1 of eyes with @entity1596 following repeated treatment with @entity619 (Ozurdex) implants. DESIGN: Retrospective, interventional study. METHODS: Twenty-two eyes of 16 pediatric @entity1 with @entity1596 were treated with 35 @entity619 implants at a tertiary referral center. Following implantations, anatomic and functional outcomes, as well as @entity2194 , were noted. Main outcome measures included best-corrected visual acuity, central retinal thickness, number and dosage of systemic immunosuppression drugs, vitreous haze score, and presence of raised intraocular pressure or @entity231 . RESULTS: Following the first implantation, average best-corrected visual acuity improved significantly from 0.55    0.08 logMAR to 0.37    0.08 logMAR (P  =  .024), central retinal thickness decreased by 219    55   m (P  = .01), and the percentage of eyes achieving a vitreous haze score of 0 increased from 41% to 88% (P  = .006). The median time to relapse following the first injection was 9  months, with a similar response achieved after each repeat implantation. @entity1 previously requiring systemic immunosuppression at the time of the first implantation were able to stop or significantly reduce the dose and number of drugs. In total there were 4  instances of @entity231 progression that were not visually significant and did not require surgical treatment and 6 cases of raised IOP, 5 of which were treated pharmacologically with no surgical intervention required and 1 that required revision of a previous filtration surgery. There were no cases of implant migration into the anterior chamber, @entity3225 , or @entity1713 . CONCLUSIONS: The use of @entity619 implants in @entity1 results in improved retinal thickness and @entity32 , which can improve vision for  several months. Repeat implantations result in continued control of the @entity32 , allowing for reduction of systemic immunosuppression with few @entity2194 .
